echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The Lancet: A study of more than 400,000 Chinese patients shows that type 2 diabetes is indeed related to the risk of "cancer king"! The younger you get, the greater the risk!

    The Lancet: A study of more than 400,000 Chinese patients shows that type 2 diabetes is indeed related to the risk of "cancer king"! The younger you get, the greater the risk!

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pancreatic cancer usually has a worse prognosis than most other tumors, with a 5-year survival rate of less than 5%.


    The global prevalence of T2DM is growing, with a reported prevalence of 12.


    This analysis was designed to study the relationship between age of onset of diabetes and duration of pancreatic cancer diabetes, to study the relationship between different levels of FBG and pancreatic cancer risk, and to study other evidence supporting a causal relationship between type 2 diabetes and pancreatic cancer in separate East Asian populations using two-sample Mendelian randomization (MR).


    This longitudinal cohort study included 428362 new patients with T2DM in Shanghai and investigated the association


    A total of 1056 cases of pancreatic cancer were found in 8 consecutive years of follow-up, with an average follow-up of 45 ± 2.


    However, relative pancreatic cancer risk is expressed in SIR, inversely proportional to the age at the onset of T2DM, and a higher SIR of 5.


    The researchers looked at the correlation between pancreatic cancer and the duration of T2DM, every


    The researchers looked at the relationship between


    MR analysis showed that T2DM was associated


    To date, this is the largest study in China to study the incidence of pancreatic cancer in new T2DM


     

    Original source:

    Baiyong Shen, et al.


     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.